Insider Transactions in Q3 2024 at G1 Therapeutics, Inc. (GTHX)
Insider Transaction List (Q3 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 18
2024
|
Glenn P Muir |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
185,358
-100.0%
|
-
|
|
Sep 18
2024
|
Glenn P Muir |
SELL
Sale (or disposition) back to the issuer
|
Direct |
20,000
-9.74%
|
-
|
|
Sep 18
2024
|
Andrew Perry Chief Commercial Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
14,232
-100.0%
|
-
|
|
Sep 18
2024
|
Andrew Perry Chief Commercial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
114,482
-88.94%
|
-
|
|
Sep 18
2024
|
Andrew Perry Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,100
+11.12%
|
-
|
|
Sep 18
2024
|
Terry L Murdock Chief Operating Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
21,150
-100.0%
|
-
|
|
Sep 18
2024
|
Terry L Murdock Chief Operating Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
124,762
-85.51%
|
-
|
|
Sep 18
2024
|
Terry L Murdock Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,900
+10.93%
|
-
|
|
Sep 18
2024
|
Mark Avagliano Chief Business Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
26,035
-100.0%
|
-
|
|
Sep 18
2024
|
Mark Avagliano Chief Business Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
236,610
-90.09%
|
-
|
|
Sep 18
2024
|
Mark Avagliano Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,600
+7.27%
|
-
|
|
Sep 18
2024
|
Norman Sharpless |
SELL
Sale (or disposition) back to the issuer
|
Direct |
20,000
-100.0%
|
-
|
|
Sep 18
2024
|
Rajesh Malik Chief Medical Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
87,450
-100.0%
|
-
|
|
Sep 18
2024
|
Rajesh Malik Chief Medical Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
89,762
-50.65%
|
-
|
|
Sep 18
2024
|
Rajesh Malik Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,900
+9.17%
|
-
|
|
Sep 18
2024
|
John E. (Jack) Bailey Jr. President and CEO |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
196,287
-100.0%
|
-
|
|
Sep 18
2024
|
John E. (Jack) Bailey Jr. President and CEO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
534,787
-73.15%
|
-
|
|
Sep 18
2024
|
John E. (Jack) Bailey Jr. President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
181,400
+19.88%
|
-
|
|
Sep 18
2024
|
John V. Umstead Chief Financial Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
19,331
-100.0%
|
-
|
|
Sep 18
2024
|
John V. Umstead Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
168,387
-89.7%
|
-
|
|
Sep 18
2024
|
Garry A Nicholson |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
14,389
-100.0%
|
-
|
|
Sep 18
2024
|
Garry A Nicholson |
SELL
Sale (or disposition) back to the issuer
|
Direct |
20,000
-58.16%
|
-
|
|
Sep 18
2024
|
Jacks Lee |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
10,000
-100.0%
|
-
|
|
Sep 18
2024
|
Jacks Lee |
SELL
Sale (or disposition) back to the issuer
|
Direct |
10,000
-50.0%
|
-
|
|
Sep 18
2024
|
Cynthia Schwalm |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
15,889
-100.0%
|
-
|
|
Sep 18
2024
|
Cynthia Schwalm |
SELL
Sale (or disposition) back to the issuer
|
Direct |
20,000
-55.73%
|
-
|
|
Sep 18
2024
|
Monica R. Thomas Chief Legal & People Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
6,674
-100.0%
|
-
|
|
Sep 18
2024
|
Monica R. Thomas Chief Legal & People Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
138,151
-95.39%
|
-
|
|
Sep 18
2024
|
Alicia Secor |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
10,000
-100.0%
|
-
|
|
Sep 18
2024
|
Alicia Secor |
SELL
Sale (or disposition) back to the issuer
|
Direct |
20,000
-66.67%
|
-
|
|
Jul 05
2024
|
Andrew Perry Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,337
-1.17%
|
$2,674
$2.51 P/Share
|
|
Jul 05
2024
|
John V. Umstead Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
527
-0.28%
|
$1,054
$2.51 P/Share
|
|
Jul 05
2024
|
Mark Avagliano Chief Business Officer |
SELL
Open market or private sale
|
Direct |
2,638
-1.08%
|
$5,276
$2.51 P/Share
|
|
Jul 05
2024
|
Rajesh Malik Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,475
-1.53%
|
$4,950
$2.51 P/Share
|
|
Jul 05
2024
|
Terry L Murdock Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
2,475
-1.9%
|
$4,950
$2.51 P/Share
|
|
Jul 05
2024
|
John E. (Jack) Bailey Jr. President and CEO |
SELL
Open market or private sale
|
Direct |
7,662
-1.37%
|
$15,324
$2.51 P/Share
|
|
Jul 01
2024
|
Terry L Murdock Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
35,000
+21.15%
|
-
|
|
Jul 01
2024
|
Andrew Perry Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
35,000
+23.5%
|
-
|
|
Jul 01
2024
|
Mark Avagliano Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
35,000
+12.51%
|
-
|
|
Jul 01
2024
|
Monica R. Thomas Chief Legal & People Officer |
BUY
Grant, award, or other acquisition
|
Direct |
35,000
+19.46%
|
-
|
|
Jul 01
2024
|
John E. (Jack) Bailey Jr. President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
105,000
+15.85%
|
-
|
|
Jul 01
2024
|
John V. Umstead Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
35,000
+15.68%
|
-
|